20.500.12556/DiRROS-29895 Treatment of alopecia areata with JAK inhibitors a review of the literature Alopecia areata (AA) is chronic autoimmune non-scarring hair loss, which can progress to alopecia totalis or universalis. Conventional treatments, such as corticosteroids and immunotherapies, often offer limited temporary benefits in moderate to severe cases. Recent advances have identified Janus kinase (JAK) inhibitors as a promising therapeutic option, targeting cytokine pathways involved in AA pathogenesis. This review explores the current evidence surrounding JAK inhibitors in the management of AA. Clinical trials and case series have demonstrated notable efficacy in promoting hair regrowth, even in extensive disease. Baricitinib and deuruxolitinib have shown particularly strong results, with significant scalp hair regrowth and acceptable safety profiles. Common adverse effects include acne, elevated lipid levels, and mild laboratory abnormalities, although long-term data remain limited. This review summarizes the mechanisms, efficacy outcomes, and safety data of various JAK inhibitors used in AA and highlights the need for further research to establish optimal dosing, treatment duration, and long-term safety. alopecia alopecia areata dermatology hair disorder JAK alopecija alopecija areata dermatologija nepravilnost las true false true Združenje slovenskih dermatovenerologov Angleški jezik Slovenski jezik Na spletni strani revije navedeno: Acta Dermatovenerologica Alpina, Pannonica et Adriatica (ISSN 1318-4458) is an open access medical journal published quarterly by the Association of Slovenian Dermatovenerologists (https://acta-apa.mf.uni-lj.si/index.php); Authors publishing in our journal retain copyright of their work under the Creative Commons Attribution License (CC BY 4.0). This license allows unrestricted use, distribution, and reproduction of the work in any medium, provided the original author(s) and copyright holder(s) are appropriately credited, and the original publication in the journal is properly cited, following established academic practices (https://acta-apa.mf.uni-lj.si/submissions.php). Neznano 2026-06-09 08:37:49 2026-06-15 16:16:12 2026-07-05 23:13:23 0000-00-00 00:00:00 2025 0 Ljubljana 0 str. 117-120 issue 3 Vol. 34 Sep. 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 2025-06-18 2025-07-31 2025-09-01 616.5:579 1318-4458 10.15570/actaapa.2025.22 260106499 https://acta-apa.mf.uni-lj.si/journals/acta-dermatovenerol-apa/papers/10.15570/actaapa.2025.22/actaapa.2025.22.pdf 1 bbdf9708-63cd-11f1-9215-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=44994 RAZ_Townsend_Jaiden_2025.pdf RAZ_Townsend_Jaiden_2025.pdf 1 B731590518F0D2360C0CB5DA090A10E6 a9e8c52477901607317b962139c43e266362db1c7ed7e986e030dc9a64f41088 be07bdd9-68c4-11f1-aebd-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45489 Združenje slovenskih dermatovenerologov Acta dermatovenerologica Alpina, Panonica et Adriatica 0 0 0